Akin-Akintayo O, et al. - The disease detection rate, diagnostic performance, and interobserver agreement of fluciclovine (¹⁸F) PET-CT and multiparametric magnetic resonance imaging (mpMR) in recurrent prostate cancer were determined. The disease detection rate for fluciclovine PET-CT in non-prostatectomy patients with biochemical failure was 94.7% versus 31.6%–36.8% for mpMR. Fluciclovine PET-CT demonstrated overall better diagnostic performance compared to mpMR for extraprostatic disease detection. In the case of treated prostate, fluciclovine PET-CT displayed high sensitivity, yet low specificity for disease detection, while mpMR had higher specificity, but low sensitivity. A higher interobserver agreement was shown with fluciclovine PET-CT compared with mpMR.